Several factors influence the survival of CML‐CP patients, including clonal chromosomal abnormalities (CCA) in Philadelphia chromosome‐positive cells, BCR‐ABL1 kinase domain mutations, non‐ABL kinase dependencies, and multidrug resistance polymorphisms. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.